首页> 外国专利> METHOD FOR PREDICTION OF COLD AIRWAY HYPERREACTIVITY CORRECTION EFFICIENCY IN BRONCHIAL ASTHMA PATIENTS WITH APPLICATION OF EXTRA-FINE AEROSOL FOR INHALATIONS OF BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE

METHOD FOR PREDICTION OF COLD AIRWAY HYPERREACTIVITY CORRECTION EFFICIENCY IN BRONCHIAL ASTHMA PATIENTS WITH APPLICATION OF EXTRA-FINE AEROSOL FOR INHALATIONS OF BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE

机译:超细气雾剂吸入丙酸倍他米松/富马酸吸入剂预测支气管哮喘患者气道高反应性矫正的方法

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to pulmonology, and can be used for prediction of efficiency of cold airway hyperreactivity correction in patients with mild and moderate bronchial asthma when using extramelic aerosol for inhalations of beclomethasone dipropionate/formoterol fumarate. For this purpose, patients undergo a questionnaire with score of 7 clinical symptoms (symptom severity is assessed in points 1 to 7) observed in winter period in contact with cold: 1 - shortness of breath; 2 - intensified dyspnoea at usual daily load on the street; 3 shows coughing gain or appearance; 4 - occurrence of pain, discomfort, chest stiffness (behind the sternum); 5 - occurrence of nasal congestion; 6 shows mucous discharge from nose; 7 is an increase in the number of doses of the used broncholytic; total score is calculated (B). That is followed by evaluating the severity of respiratory reaction in response to inhalation of 400 mcg of β2-adrenomimetic salbutamol by changing the volume of forced exhalation in 1 second (in % of the initial value) after performing the test with broncholytic (ΔFEV1B). Forecast is carried out by comparing the value D calculated using the equation D = 2.361 × B + 0.397 × ΔFEV1B, with its boundary value (+55.88). If D is less than the boundary value, efficiency of correction of cold airway hyperreactivity is predicted, if D is equal to or exceeds the limit value, correction inefficiency is predicted.;EFFECT: method enables optimizing the therapeutic approach to the patients with mild and moderate bronchial asthma with cold airway hyperreactivity with reducing the length of selecting the optimal method of treatment.;1 cl, 3 tbl, 2 ex
机译:领域:药物:本发明涉及医学,即肺病学,当使用散剂气雾剂吸入丙酸倍氯米松/富马酸福莫特罗时,可用于预测轻度和中度支气管哮喘患者冷气道反应过度的有效性。为此,患者接受问卷调查,在冬季接触感冒时观察到7种临床症状的评分(症状严重程度在1至7点进行评估):1-呼吸急促; 2-在大街上通常的日常负荷下呼吸困难加剧;图3显示了咳嗽声或外观。 4-出现疼痛,不适,胸部僵硬(胸骨后); 5-鼻塞的发生;图6示出了从鼻子排出的粘液。图7是所使用的支气管溶出剂的剂量数量的增加;计算总分(B)。随后,通过在执行后1秒钟内改变强制呼气的量(以初始值的%),评估吸入400 mcgβ 2 -肾上腺素沙丁胺醇后的呼吸反应严重程度用支气管溶血(ΔFEV 1B )进行测试。通过将使用公式D = 2.361×B + 0.397×ΔFEV 1B 计算的值D与边界值(+55.88)进行比较来进行预测。如果D小于边界值,则可预测出冷气道反应过度的矫正效率,如果D等于或超过极限值,则可预测矫正效率低下。;效果:该方法可优化轻度和轻度患者的治疗方法中度支气管哮喘伴冷气道高反应性并减少选择最佳治疗方法的时间。; 1 cl,3 tbl,2 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号